FIELD: biotechnology.
SUBSTANCE: disclosed are antibodies which specifically bind a molecule containing scFv to CD19, and compositions containing said antibodies. Also disclosed are polynucleotides coding antibodies, expressing vectors and host cells containing said polynucleotides, a method of producing antibodies. Invention also relates to use of said antibodies to determine the presence or absence of a polypeptide containing an anti-CD19 scFv, or cells containing it.
EFFECT: invention can be used to detect expression of CARs to CD19, containing scFv from clone of antibody 4G7, on engineered T-cells or in in vitro assays.
27 cl, 8 dwg, 8 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DOSES OF ALLOGENEIC T-CELLS WITH CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2776322C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| CELL | 2015 |
|
RU2768019C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
